secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anixa Biosciences Inc (ANIX)
CIK:        0000715446
Form:       8-K
Filed at:   2022-08-17T23:59:59+00:00
Accession:  0001493152-22-023285
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Anixa Biosciences doses first patient in Phase 1 CAR-T trial for ovarian cancer
-------------------------------------------------------------------------------

- First patient dosed in Phase 1 trial of novel CER-T therapy for ovarian cancer at Moffitt Cancer Center.
- Dose-escalation study to evaluate safety, maximum tolerated dose, and preliminary efficacy.
- Trial targets follicle stimulating hormone receptor (FSHR) on ovarian cells.
- Up to 48 patients may be enrolled in the study.
- CER-T approach differs from traditional CAR-T by targeting an endocrine receptor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/0001493152-22-023285-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/715446/000149315222023285/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-023285

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer